Abstract: The present disclosure provides compounds useful for the inhibition of KRAS. The compounds have a general Formula I: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.

Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.

Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.

Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula (I): wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.

Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I?: wherein the variables of Formula I? are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.

Abstract: A charging and field supplement circuit for superconducting magnets based on a pulsed current includes a capacitor charging circuit, an energy-storage capacitor, a capacitor discharging circuit, a superconducting magnetic energy storage circuit, and a superconducting persistent-current switch. Two output ends of the capacitor charging circuit are respectively connected to two ends of the energy-storage capacitor. Two input ends of the capacitor discharging circuit are respectively connected to the two ends of the energy-storage capacitor. Two output ends of the capacitor discharging circuit are respectively connected to two input ends of the superconducting magnetic energy storage circuit. Two output ends of the superconducting magnetic energy storage circuit are respectively connected to two input ends of the superconducting persistent-current switch. Two output ends of the superconducting persistent-current switch are configured to charge and magnetize a target superconducting magnet.

Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

Abstract: A charging and field supplement circuit for superconducting magnets based on a pulsed current includes a capacitor charging circuit, an energy-storage capacitor, a capacitor discharging circuit, a superconducting magnetic energy storage circuit, and a superconducting persistent-current switch. Two output ends of the capacitor charging circuit are respectively connected to two ends of the energy-storage capacitor. Two input ends of the capacitor discharging circuit are respectively connected to the two ends of the energy-storage capacitor. Two output ends of the capacitor discharging circuit are respectively connected to two input ends of the superconducting magnetic energy storage circuit. Two output ends of the superconducting magnetic energy storage circuit are respectively connected to two input ends of the superconducting persistent-current switch. Two output ends of the superconducting persistent-current switch are configured to charge and magnetize a target superconducting magnet.

Abstract: A composite superconducting tape, a combination and preparation method thereof, and a defect bypassing or an end joint connection method. The composite superconducting tape includes a plurality of superconducting tapes, including a first superconducting tape and a second superconducting tape. The first superconducting tape includes a first superconducting layer, and the second superconducting tape includes a second superconducting layer. A side of the first superconducting tape close to the first superconducting layer is bonded with a side of the second superconducting tape close to the second superconducting layer along a length direction. The first superconducting tape is misaligned with the second superconducting tape along a width direction, such that the side of the first superconducting tape has a first vacant area for bonding with a second conductive tape, and the side of the second superconducting tape has a second vacant area for bonding with the first conductive tape.

Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

Abstract: Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:

Abstract: Compounds having the following Formula (I), or a pharmaceutically acceptable salt or pharmaceutically acceptable tautomer thereof, and methods of their use and preparation are disclosed:

Abstract: Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:

Abstract: Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:

Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.